Aarey Drugs & Pharmaceuticals enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


307	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
1.4	1.4	1.5	1.6	0.7
50.0	50.0	34.9	31.4	37.7
356	—	—	—	—
48.6	48.6	33.4	29.8	37.0
₹125.12	—	—	—	—

200	200	173	164	155
24.9%	24.9%	20.1%	19.1%	24.3%
0.14×	—	—	—	—

0.86×	—	—	—	—
52.40×	—	—	—	—
99.46×	—	—	—	—
415	472	474	396	62.5
6.8	7.2	2.3	4.5	1.5
3.6	4.3	0.3	2.8	0.8
—	10.1	9.7	7.9	−39.1
−2.3	−2.3	9.7	7.9	−40.1
—	−3.6	8.3	7.4	−40.3
—	12.4	0.0	0.0	1.0

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

AAREYDRUGS₹108.05

Aarey Drugs & Pharmaceuticals Limited

· Pharma & Health

₹ CrorePeersNECLIFE NATCAPSUQ MEDICAMEQ MEDICO BALPHARMA ALPA KREBSBIO HALEOSLABSMcap ₹307 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	307.4
- Cash, Equiv & ST Investments	0.7	1.6	1.5	1.4	1.4
+ Total Debt	37.7	31.4	34.9	50.0	50.0
Enterprise Value	—	—	—	—	356.0
Net Debt (memo)	37.0	29.8	33.4	48.6	48.6
EV per Share	—	—	—	—	125.12

Total Capital	155.1	164.1	173.3	200.4	200.4
Total Debt/Total Capital	24.31	19.10	20.11	24.93	24.93
Total Debt/EV	—	—	—	—	0.14

EV/Sales	—	—	—	—	0.86
EV/EBITDA	—	—	—	—	52.40
EV/EBIT	—	—	—	—	99.46
Reference Items — Trailing FY Values
Sales	62.5	395.6	473.9	472.3	414.7
EBITDA	1.5	4.5	2.3	7.2	6.8
EBIT	0.8	2.8	0.3	4.3	3.6
Operating Cash Flow	-39.1	7.9	9.7	10.1	—
Free Cash Flow	-40.1	7.9	9.7	-2.3	-2.3
FCFF (free cash flow to the firm)	-40.3	7.4	8.3	-3.6	—
Capital Expenditure	1.0	0.0	0.0	12.4	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.